Please use this identifier to cite or link to this item: https://apo.ansto.gov.au/dspace/handle/10238/14077
Title: Towards epithermal boron neutron capture therapy for cancer
Authors: Allen, BJ
Keywords: Neutron capture therapy
Neoplasms
Boron
Brain
Neutron beams
Radiotherapy
Melanomas
Irradiation
Issue Date: 1-May-1994
Publisher: The Institution of Engineers Australia
Citation: Allen, B. J. (1994). Towards epithermal boron neutron capture therapy for cancer. Paper presented to the 9th Pacific Basin Nuclear Conference : Nuclear energy, science and technology Pacific partnership, Sydney, Australia, May 1-6 1994. In McDonald, N. R. (ed), Proceedings, 9th Pacific Basin Nuclear Conference: Nuclear energy, science & technology Pacific partnership, (pp.433-440). Australia: The Institution of Engineers Australia.
Abstract: Progress in the treatment of local disseminating cancer such as high grade brain tumours is poor, and the ability to kill individual cancer cells in the midst of normal cells has not been achieved. Binary therapies hold the most promise of this, and of these Boron Neutron Capture Therapy is the most advanced. Epithermal neutron beams are essential for outpatient treatment of high grade brain tumours and these are now installed and being characterised in Europe and the USA, and are at the design stage in Australia. These beams would allow the bilateral irradiation of the entire brain, and as such are ideally suited for the prophylactic therapy of subclinical metastases. When coupled with appropriate cancer affined boron compounds, therapeutic ratios of 2-3 should be achieved. At present the only source of an epithermal neutron beam is a nuclear reactor. The Euratom reactor at Petten and the Brookhaven Medical Reactor have been retrofitted with filters to produce an epithermal neutron beam. These beams have been characterised and used in dose escalation studies with dogs to study normal tissue tolerance using borocaptate (BSH). Another beam is available at the MIT medical research reactor. Clinical trials at Petten for glioblastoma with BSH and at MIT using boronophenylalanine for melanoma metastases to the extremities are expected to commence this year. The state of the art of reactor based BNCT is reviewed and the potential for a major change in the prognosis of local control of disseminating cancer is explored.
Description: Physical copy held by ANSTO Library at DDC 621.48/91
URI: https://apo.ansto.gov.au/dspace/handle/10238/14077
ISBN: 858256029
Appears in Collections:Conference Publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.